期刊文献+

自拟固冲汤联合福乃得治疗冲任不固型缺铁性贫血临床观察 被引量:9

Therapeutic Effect of Self-prescribed Guchong Decoction Combined with Ferroids for Iron Deficiency Anemia Patients with Unconsolidation of Thoroughfare and Conception Vessels
原文传递
导出
摘要 【目的】观察自拟固冲汤联合福乃得治疗冲任不固型缺铁性贫血(IDA)的临床疗效。【方法】将70例冲任不固型IDA患者随机分为治疗组和对照组,每组各35例。对照组给予服用福乃得治疗,治疗组在对照组治疗基础上加用自拟固冲汤口服治疗,2组均以1个月为1个疗程,共治疗2个疗程。治疗前后观察2组患者的血常规[红细胞(RBC)、血红蛋白(HGB)、平均红细胞体积(MCV)、平均红细胞血红蛋白量(MCH)、平均红细胞血红蛋白浓度(MCHC)、白细胞(WBC)、血小板(PLT)]+网织红细胞计数(Ret)、铁代谢指标[血清铁(SI)、血清铁蛋白(SF)、总铁结合力(TIBC)]等,治疗期间密切观察2组患者出现的不良反应,疗程结束后评价2组患者的西医临床疗效及中医证候疗效,治疗结束后3个月随访观察2组患者的复发情况。【结果】(1)脱落情况:治疗组因患者短期停药脱落1例,对照组相同原因脱落2例。(2)疗效情况:治疗2个月,2组均取得较好疗效,治疗组与对照组西医疗效的临床治愈率分别为82.4%和60.6%,中医证候疗效的临床治愈率分别为94.1%和51.5%,治疗组的西医疗效和中医证候疗效均优于对照组,差异均有统计学意义(P<0.05或P<0.01)。(3)血常规情况:治疗后,2组患者的RBC、HGB、Ret、MCV、MCH、MCHC、WBC水平均明显升高(P<0.01),PLT水平明显降低(P<0.01),但治疗后组间比较,差异均无统计学意义(P>0.05)。(4)铁代谢指标情况:治疗后,治疗组患者的SF、SI水平较治疗前明显升高(P<0.01),TIBC水平较治疗前明显降低(P<0.01),而对照组患者治疗后仅SF、SI水平升高(P<0.01),治疗组在升高SF、SI水平和降低TIBC水平方面均优于对照组(P<0.05或P<0.01),表明治疗组对铁代谢指标的改善作用优于对照组。(5)治疗组患者的不良反应发生率及复发率均明显低于对照组,差异均有统计学意义(P<0.01)。【结论】应用自拟固冲汤联合福乃得治疗冲任不固型IDA疗效肯� Objective To observe the clinical efficacy of self-prescribed Guchong Decoction combined with Ferroids for the treatment of iron deficiency anemia(IDA) patients with unconsolidation of thoroughfare and conception vessels. Methods A total of 70 IDA patients with unconsolidation of thoroughfare and conception vessels were randomized into treatment group and control group,35 cases in each group. The control group was given oral use of Ferroids, and the treatment group was treated with self-prescribed Guchong Decoction combined with Ferroids. One month constituted a treatment course,and both groups were treated for 2 courses.Before and after treatment,we compared the parameters of blood routine test for red blood cells(RBC),hemoglobin(HGB), mean corpuscular volume(MCV), mean corpuscular hemoglobin(MCH), MCH concentration(MCHC),white blood cells(WBC) and platelets,as well as reticulocytes(Ret) and iron metabolism indexes including serum iron(SI),serum ferritin(SF),and total iron-binding capacity(TIBC). The adverse reaction was monitored during the treatment. After treatment,both western medicine clinical efficacy and traditional Chinese medicine(TCM) syndrome clinical efficacy of the two groups were evaluated. A 3-month follow-up was carried out after treatment to evaluate the recurrence rate. Results(1)Drop-out occurred in one case from the treatment group and in 2 cases from the control group because of short-term medication suspension.(2)After treatment for2 months, western medicine clinical cure rate of the treatment group was 82.4% and that of the control group was 60.6%, and TCM syndrome clinical cure rate of the treatment group was 94.1% and that of the control group was 51.5%,the difference being significant(P 0.05 or P 0.01).(3) The levels of RBC,HGB,Ret,MCV,MCH,MCHC,and WBC of the two groups were obviously increased after treatment(P 0.01),and PLT level was markedly decreased(P 0.01) as compared with those before treatment, but the inter
出处 《广州中医药大学学报》 CAS 2018年第1期13-18,共6页 Journal of Guangzhou University of Traditional Chinese Medicine
基金 国家自然科学基金资助项目(编号:81473513 81673799)
关键词 固冲汤 福乃得 冲任不固 缺铁性贫血 中西医结合 Guchong Decoction Ferroids unconsolidation of thoroughfare and conception vessels irondeficiency anemia integrative Chinese and western medicine
  • 相关文献

参考文献8

二级参考文献26

  • 1Bergamaschi G,Villani L.Serum hepcidin:a novel diagnostic tool in disorders of iron metaboiism[J].Haematologica,2009,94(12):1631-1633. 被引量:1
  • 2Ravasi G,Pelucchi S,Trombini P,et al.Hepcidin expression in iron overload diseases is variably modulated by circulating cactors[J].PLo S One,2012,7(5):e36425. 被引量:1
  • 3Chung B,Chaston T.Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1macrophages and intestinal Caco-2 cells[J].JNutr,2009,139(8):1457-1462. 被引量:1
  • 4Anderson GJ,Frazer DM.Recent advances in intestinal iron transport[J].Curr Gastroenterol Rep,2005,7(5):365-372. 被引量:1
  • 5Sun CC,Vaja V,Babitt JL,et al.Targeting the hepcidin-ferroportin axis to develop newtreatment strategies for anemia of chronic disease and anemiaof inflammation[J].Am J Hematol,2012,87(4):392-400. 被引量:1
  • 6Finberg KE.Unraveling mechanisms regulating systemic iron homeostasis[J].Hematology Am Soc Hematol Educ Program,2011,2011:532-537. 被引量:1
  • 7Elizabeta N,Tomas G.The role of hepcidin in iron metabolism[J].Acta Haematol,2009,122(2/3):78-86. 被引量:1
  • 8Nicolas G,Bennoun M.Severe iron deficiency anemia in transgenic mice expressing liver hepcidin[J].Proc Natl Acad Sci U S A,2002,99(7):4596-4601. 被引量:1
  • 9Pasricha SR,Mc Quilten Z.Serumhepcidin as a diagnostic test of irondeficiency in premenopausal female blood donors[J].Haematologica,2011,96(8):1099-1105. 被引量:1
  • 10Nemeth E,Rivera S,Gabayan V,et al.IL-6 mediates hypoferremia of inflamm ation by inducing the synthesis of the iron ragulatoey hormone hepcidin[J].Clin Invest,2004,113(9):1271-1276. 被引量:1

共引文献21

同被引文献121

引证文献9

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部